JPWO2022098845A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022098845A5 JPWO2022098845A5 JP2023527029A JP2023527029A JPWO2022098845A5 JP WO2022098845 A5 JPWO2022098845 A5 JP WO2022098845A5 JP 2023527029 A JP2023527029 A JP 2023527029A JP 2023527029 A JP2023527029 A JP 2023527029A JP WO2022098845 A5 JPWO2022098845 A5 JP WO2022098845A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- tcr
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 618
- 229920001184 polypeptide Polymers 0.000 claims description 349
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 349
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 349
- 108020004707 nucleic acids Proteins 0.000 claims description 97
- 102000039446 nucleic acids Human genes 0.000 claims description 97
- 150000007523 nucleic acids Chemical class 0.000 claims description 97
- 108091008874 T cell receptors Proteins 0.000 claims description 80
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 108010026122 HLA-A*33 antigen Proteins 0.000 claims description 4
- 108010018475 HLA-A31 antigen Proteins 0.000 claims description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 102200048928 rs121434568 Human genes 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims description 2
- 206010038111 Recurrent cancer Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 24
- 230000009258 tissue cross reactivity Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110116P | 2020-11-05 | 2020-11-05 | |
| US63/110,116 | 2020-11-05 | ||
| PCT/US2021/058019 WO2022098845A1 (en) | 2020-11-05 | 2021-11-04 | Engineered t cell receptors targeting egfr antigens and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023548556A JP2023548556A (ja) | 2023-11-17 |
| JPWO2022098845A5 true JPWO2022098845A5 (https=) | 2024-11-12 |
| JP2023548556A5 JP2023548556A5 (https=) | 2024-11-12 |
Family
ID=81458279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527029A Pending JP2023548556A (ja) | 2020-11-05 | 2021-11-04 | Ｅｇｆｒ抗原を標的とする操作されたｔ細胞受容体および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240009241A1 (https=) |
| EP (2) | EP4570256A3 (https=) |
| JP (1) | JP2023548556A (https=) |
| KR (1) | KR20230104220A (https=) |
| CA (1) | CA3200661A1 (https=) |
| WO (1) | WO2022098845A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116457371A (zh) * | 2020-10-07 | 2023-07-18 | 多安生物治疗有限公司 | T细胞受体、包含t细胞受体的免疫细胞及其使用方法 |
| US20260078163A1 (en) * | 2022-09-06 | 2026-03-19 | Board Of Regents, The University Of Texas System | T-cell receptor that targets egfr mutation and methods of using the same |
| WO2024123794A2 (en) * | 2022-12-05 | 2024-06-13 | Board Of Regents, The University Of Texas System | A t cell receptor recognizing a her2 mutation presented on hla-a*02:01 and methods of use |
| WO2026011097A1 (en) * | 2024-07-03 | 2026-01-08 | Yale University | Antibody drug conjugates comprising tcr-vbeta specific therapeutic molecules and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| DE69334225D1 (de) | 1992-07-07 | 2008-07-31 | Japan Tobacco Inc | Verfahren zur transformation einer monokotyledon pflanze |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| WO1994002620A2 (en) | 1992-07-27 | 1994-02-03 | Pioneer Hi-Bred International, Inc. | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| CA2277278A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| CN106103711A (zh) * | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
| JP6464255B2 (ja) | 2014-08-04 | 2019-02-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｔ細胞活性化抗原結合分子 |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| AU2017225733A1 (en) * | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore |
| CN110139873A (zh) * | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| AU2018318303A1 (en) * | 2017-08-18 | 2020-04-09 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| US20220175899A1 (en) * | 2019-04-11 | 2022-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer |
| CN111848782A (zh) * | 2019-04-25 | 2020-10-30 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| EP3962939A4 (en) * | 2019-05-03 | 2023-05-17 | Gigamune, Inc. | MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM |
-
2021
- 2021-11-04 JP JP2023527029A patent/JP2023548556A/ja active Pending
- 2021-11-04 KR KR1020237018697A patent/KR20230104220A/ko active Pending
- 2021-11-04 CA CA3200661A patent/CA3200661A1/en active Pending
- 2021-11-04 EP EP25167367.9A patent/EP4570256A3/en active Pending
- 2021-11-04 EP EP21890044.7A patent/EP4240377A4/en not_active Withdrawn
- 2021-11-04 US US18/251,881 patent/US20240009241A1/en active Pending
- 2021-11-04 WO PCT/US2021/058019 patent/WO2022098845A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10118964B2 (en) | Construction and application of bispecific antibody HER2xCD3 | |
| US9777073B2 (en) | Construction and application of bispecific antibody EpCAM×CD3 | |
| JP7510246B2 (ja) | 抗グリピカン３抗体およびその使用 | |
| CN104592392B (zh) | 一种双特异性抗体EpCAM×CD3的构建及应用 | |
| EP3600407A1 (en) | Improved antigen binding receptors | |
| IL285286B2 (en) | Transpase polypeptides and uses thereof | |
| CN114651012A (zh) | 与CD117/c-KIT和CD3结合的双特异性结合剂 | |
| CN104592391B (zh) | 一种双特异性抗体EpCAM×CD3的构建及应用 | |
| CN114072426B (zh) | 抗cd47/抗pd-1双特异抗体及其制备方法和应用 | |
| CN107033248A (zh) | 识别癌胚抗原的嵌合抗原受体及其应用 | |
| CN104788567A (zh) | 一种靶向鼠T淋巴细胞CD3和人肿瘤抗原EpCAM的双特异性抗体制备方法及应用 | |
| CN104558192A (zh) | 一种双特异性抗体her2xcd3的构建及应用 | |
| CN104829725A (zh) | 一种双特异性抗体cd133×cd3的构建及应用 | |
| WO2024001470A1 (zh) | 靶向b7-h3的抗体及其用途 | |
| WO2023051414A1 (zh) | 靶向间皮素的抗体及其用途 | |
| CN111848806B (zh) | Egfr-cd3双功能抗体及其应用 | |
| WO2020259535A1 (zh) | 抗cd47/抗tigit双特异抗体及其制备方法和应用 | |
| CN114286863A (zh) | 一种双特异性嵌合抗原受体 | |
| JPWO2022098845A5 (https=) | ||
| JPWO2021236548A5 (https=) | ||
| WO2024192704A1 (en) | Nanobodies that bind to gprc5d and uses thereof | |
| CN117924519A (zh) | 靶向cd138的嵌合抗原受体 | |
| CN111434691A (zh) | Pd-l2单克隆抗体及其应用 | |
| US20240050567A1 (en) | Modified immune effector cell and use thereof | |
| CN117304320A (zh) | 靶向小鼠clec12b蛋白的纳米抗体及其应用 |